On June 3, 2022 Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, reported that the Company plans to hold a clinical update call on June 13 after the European Hematology Association (EHA) (Free EHA Whitepaper) 2022 Hybrid Congress (EHA 2022) as the data is subject to meeting’s embargo policy until June 12 (Press release, Gracell Biotechnologies, JUN 3, 2022, View Source [SID1234615552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The management team intends to highlight clinical data from three investigator-initiated trials (IIT) for its BCMA/CD19 dual-targeting FasTCAR-T candidate GC012F and allogeneic TruUCAR-T candidate GC502 that will be presented at 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (ASCO 2022) Annual Meeting and EHA (Free EHA Whitepaper) 2022 as follows:

Updated clinical data from a multicenter IIT evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in oral abstract presentations on June 5 at ASCO (Free ASCO Whitepaper) 2022 and on June 12 at EHA (Free EHA Whitepaper) 2022
Initial clinical data from an ongoing IIT evaluating GC012F for the treatment of relapsed/refractory B-NHL in a poster presentation on June 10 at EHA (Free EHA Whitepaper) 2022
Updated data with longer follow-up of GC502 in relapsed/refractory B-ALL in a poster presentation on June 10 at EHA (Free EHA Whitepaper) 2022